The 2nd domestic DPP-4 inhibitor attracted attention with high expectation of global commercialization
The DPP-4(dipepitdyl peptidase-4) diabetes new drug developed by Dong-A ST for the second time as a domestic company, Evogliptin, is expected to become a role model of the global commercialization.
This is because there is now a high chance that the product will become the future devoted product...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
